Use of tlr agonists and/or type 1 interferons to alleviate...

Details Use of tlr agonists and/or type 1 interferons to alleviate... Use of tlr agonists and/or type 1 interferons to alleviate...

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 31/4745 (2006.01) A61K 31/5377 (2006.01) A61K 35/66 (2006.01) A61K 38/21 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) A61P 37/04 (2006.01) C07K 14/705 (2006.01) C07K 14/715 (2006.01)

Patent

CA 2691089

Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/r TLR agonist).

La présente invention concerne des procédés améliorés (plus sûrs et plus efficaces) de thérapies utilisant des agonistes du TNF-R, par exemple, des agonistes du CD40. Ces procédés permettent d'ajouter une quantité d'un interféron du type 1 et/ou d'un agoniste des TLR qui est efficace pour prévenir ou réduire la toxicité (la toxicité hépatique) qui peut autrement apparaître chez certains patients traités avec l'agoniste du TNF-R utilisé en monothérapie (sans l'interféron de type 1 et/ou l'agoniste des TLR).

Affiliated with

Also associated with

Rating

Use of tlr agonists and/or type 1 interferons to alleviate... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of tlr agonists and/or type 1 interferons to alleviate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tlr agonists and/or type 1 interferons to alleviate... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1792398